XML 52 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2016
Mar. 31, 2016
Sep. 30, 2015
Jun. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Revenue $ 5,191.7   $ 4,959.7   $ 15,461.6 $ 14,583.1
Collaboration and other revenue 216.5   215.2   607.3 644.7
Income before income taxes 970.7   1,047.8   2,482.0 2,345.4
Acquired in-process research and development 0.0   0.0   0.0 (336.0)
Asset impairment, restructuring, and other special charges (45.5)   (42.4)   (234.9) (222.8)
Foreign Currency Transaction Gain (Loss), Realized 0.0 $ (203.9) 0.0   (203.9) 0.0
Nonoperating Income (Expense) 27.2   86.5   (100.6) 55.9
Cost of sales (1,400.9)   (1,236.9)   (4,188.9) (3,648.0)
Marketing, selling, and administrative (1,565.4)   (1,575.7)   (4,661.9) (4,734.6)
Debt extinguishment loss 0.0   0.0 $ 166.7 0.0 166.7
Animal Health [Member]            
Income before income taxes 104.9   139.8   464.3 443.1
Animal Health Products [Member]            
Revenue 706.2   778.8   2,320.5 2,369.3
Human Pharmaceutical Products [Member]            
Revenue 4,485.5   4,180.9   13,141.1 12,213.8
Income before income taxes 1,089.0   1,124.1   2,975.3 3,224.0
Operating Segments [Member]            
Income before income taxes 1,193.9   1,263.9   3,439.6 3,667.1
Corporate, Non-Segment [Member]            
Acquired in-process research and development 0.0   0.0   0.0 (336.0)
Asset impairment, restructuring, and other special charges (45.5)   (42.4)   (234.9) (222.8)
Foreign Currency Transaction Gain (Loss), Realized 0.0   0.0   (203.9) 0.0
Amortization of Intangible Assets (177.7)   (152.5)   (518.8) (457.2)
Other Pharmaceuticals [Member] | Human Pharmaceutical Products [Member]            
Revenue 80.4   48.8   213.0 168.5
Other Endocrinology [Member] | Human Pharmaceutical Products [Member]            
Revenue 262.8   249.4   734.5 696.9
Total Endocrinology [Member] | Human Pharmaceutical Products [Member]            
Revenue 1,975.8   1,786.4   5,690.9 5,050.6
Humalog [Member] | Human Pharmaceutical Products [Member]            
Revenue 640.8   705.0   1,949.0 2,043.3
Humulin [Member] | Human Pharmaceutical Products [Member]            
Revenue 322.0   316.7   1,010.6 948.8
Forteo [Member] | Human Pharmaceutical Products [Member]            
Revenue 391.2   348.9   1,077.5 970.4
Trulicity [Member] [Member] | Human Pharmaceutical Products [Member]            
Revenue 243.6   73.7   588.5 136.2
Trajenta (BI) [Member] | Human Pharmaceutical Products [Member]            
Collaboration and other revenue 115.4   92.7   330.8 255.0
Cymbalta [Member] | Human Pharmaceutical Products [Member]            
Revenue 313.5 [1]   242.9   748.7 [1] 804.0
Zyprexa [Member] | Human Pharmaceutical Products [Member]            
Revenue 148.9   237.9   572.3 711.2
Strattera [Member] | Human Pharmaceutical Products [Member]            
Revenue 198.8   196.9   611.5 562.4
Other Neuroscience [Member] | Human Pharmaceutical Products [Member]            
Revenue 47.3   46.8   137.4 136.0
Total Neuroscience [Member] | Human Pharmaceutical Products [Member]            
Revenue 708.5   724.5   2,069.9 2,213.6
Alimta [Member] | Human Pharmaceutical Products [Member]            
Revenue 570.4   628.5   1,741.7 1,865.8
Erbitux [Member] | Human Pharmaceutical Products [Member]            
Revenue 184.6   85.9   533.3 308.8
Collaboration and other revenue 28.7   88.2   77.5 286.2
Effient [Member] | Human Pharmaceutical Products [Member]            
Revenue 127.7   132.1   394.3 382.7
Other Oncology [Member] | Human Pharmaceutical Products [Member]            
Revenue 33.3   35.7   100.3 101.8
Total Oncology [Member] | Human Pharmaceutical Products [Member]            
Revenue 947.3   861.3   2,812.3 2,542.8
Cialis [Member] | Human Pharmaceutical Products [Member]            
Revenue 588.2   566.1   1,795.3 1,672.3
Other Cardiovascular [Member] | Human Pharmaceutical Products [Member]            
Revenue 57.6   61.7   165.4 183.3
Total Cardiovascular [Member] | Human Pharmaceutical Products [Member]            
Revenue 773.5   759.9   2,355.0 2,238.3
Cyramza [Member] | Human Pharmaceutical Products [Member]            
Revenue 159.0   111.2   437.0 266.4
Fair Value Adjustment to Inventory [Member] | Corporate, Non-Segment [Member]            
Cost of sales 0.0   (21.2)   0.0 (153.0)
Adjustment to Return Reserve [Member] | Cymbalta [Member] | Human Pharmaceutical Products [Member]            
Revenue 145.0       175.0  
Long-term Debt [Member] | Corporate, Non-Segment [Member]            
Nonoperating Income (Expense) $ 0.0   $ 0.0 [2]   $ 0.0 $ (152.7) [2]
[1] (1) Cymbalta revenues include reductions to the reserve for expected product returns of approximately $145 million and $175 million during the three and nine months ended September 30, 2016, respectively.
[2] (2) We recognized pretax net charges of $152.7 million for the nine months ended September 30, 2015, attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the related issuance of euro-denominated notes.